LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Akciju saraksts・Smith & Nephew PLC ADR

Smith & Nephew PLC ADR

Slēgts

30.09 -0.33

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

30.04

Max

30.52

Galvenie mērījumi
By Trading Economics
Ienākumi	35M 331M
Pārdošana	203M 3.2B
P/E Sektora vidējais	21.761 49.8
Dividenžu ienesīgums	2.53
Peļņas marža	10.368
Darbinieki	16,988
EBITDA	133M 856M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+10.91% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.53% 2.25%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2B 13B
Iepriekšējā atvēršanas cena	30.42
Iepriekšējā slēgšanas cena	30.09

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

26.64 / 28.37 Atbalsts un pretestība

Smith & Nephew PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. maijs 23:58 UTC

Peļņas

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026. g. 7. maijs 22:57 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026. g. 7. maijs 23:52 UTC

Peļņas

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026. g. 7. maijs 23:45 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 7. maijs 23:39 UTC

Tirgus saruna

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026. g. 7. maijs 23:28 UTC

Tirgus saruna

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026. g. 7. maijs 23:11 UTC

Peļņas

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026. g. 7. maijs 23:06 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026. g. 7. maijs 23:05 UTC

Peļņas

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026. g. 7. maijs 23:04 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026. g. 7. maijs 23:02 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026. g. 7. maijs 23:00 UTC

Tirgus saruna

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026. g. 7. maijs 22:42 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026. g. 7. maijs 22:33 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026. g. 7. maijs 22:32 UTC

Peļņas

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie: 68% of FY Income From International >MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026. g. 7. maijs 22:29 UTC

Peļņas

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026. g. 7. maijs 22:26 UTC

Peļņas

Macquarie to End Share Buyback Extended in November>MQG.AU

2026. g. 7. maijs 22:25 UTC

Peļņas

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Salīdzinājums

Cenas izmaiņa

Smith & Nephew PLC ADR Prognoze

Cenas mērķis

By TipRanks

10.91% augšup

Prognoze 12 mēnešiem

Vidējais 33.56 USD 10.91%

Augstākais 35.11 USD

Zemākais 32 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

26.64 / 28.37Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.